Common questions
Ipamorelin FAQ: the safety, the science, and the practical questions
Direct, cited answers to the questions people actually ask about ipamorelin.
What are the risks of ipamorelin?
The main documented risk is the gap in evidence itself. The only human efficacy trial (NCT00672074, n = 114) failed, and no long-term human safety data exist [3]. Mechanism-based cautions apply to anyone with active cancer, diabetes, or heart disease, and a class-level rat study showed heart-muscle damage with a related ghrelin-receptor agonist [6]. Material from unregulated suppliers adds an unverified-purity risk.
What are the downsides of ipamorelin?
The biggest downside is that it is unproven where it counts: the one human trial that tested a real outcome missed its endpoint [3]. Other downsides include no approved use anywhere, no long-term safety database, a class-level cardiotoxicity signal in rats [6], tightened compounding access since 2024, and a prohibition in sport. Reported side effects (flushing, hunger, mild puffiness) are minor but real to users.
Does ipamorelin cause cancer?
No study shows ipamorelin causes cancer, and none has tested the question in humans. The concern is theoretical: growth hormone raises IGF-1, a signal that promotes cell growth [4], so chronically raising GH pulses could in principle feed pre-existing tumors. This is a mechanistic, class-level caution — not an observed finding in any ipamorelin study [1]. Active or recent cancer is listed as a reason for caution for this reason.
What are the side effects of CJC-1295 and ipamorelin?
Reported side effects of the CJC-1295 + ipamorelin combination are mostly mild and anecdotal: facial flushing soon after injecting, increased hunger, mild water retention, tingling in the hands and feet, injection-site irritation, and occasional early fatigue or dizziness. None come from a controlled human trial of the combination, which has never been run [15]. Ipamorelin's one human trial showed no specific safety signal over seven days [3].
Does ipamorelin affect cortisol or prolactin?
No — and that is its defining feature. In its founding characterization, ipamorelin released growth hormone potently in rats and pigs (pig ED50 2.3 nmol/kg versus 3.9 nmol/kg for GHRP-6) yet did not raise ACTH, cortisol, or prolactin even at doses more than 200 times its GH-active dose [1]. This selectivity is exactly what distinguishes it from older GH-releasing peptides like GHRP-6 and GHRP-2.
What is ipamorelin?
Ipamorelin is a synthetic five-amino-acid peptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that releases growth hormone by activating the ghrelin receptor (GHS-R1a) [1]. It is the most selective growth hormone secretagogue characterized — raising GH without raising cortisol or prolactin [1]. It was developed by Novo Nordisk in the 1990s, has never been approved as a drug, and is sold only as a research chemical.
What does ipamorelin do for you?
In studies, ipamorelin triggers a pulse of growth hormone through the ghrelin receptor, without raising cortisol or prolactin [1]. In animals it increased longitudinal bone growth in rats [4] and reduced chemotherapy-driven weight loss in ferrets [5]. In the single human efficacy trial it did not speed bowel recovery after surgery [3]. Users anecdotally report better sleep and recovery, but those are not clinical findings.
What is ipamorelin peptide?
Ipamorelin peptide is a wholly synthetic pentapeptide — five amino acids, molecular weight about 712 Da — derived from GHRP-1 and engineered with two D-amino acids and a non-natural amino acid (Aib) for stability [1]. It mimics the natural hunger hormone ghrelin at the GHS-R1a receptor to release growth hormone. It is not an endogenous human peptide and has no approved medical use.
Does ipamorelin reduce belly fat?
No human study has tested ipamorelin for belly fat. In a 2024 ferret study, ipamorelin (1–3 mg/kg) reduced chemotherapy-driven body-weight loss by about 24% — the opposite context from fat loss [5]. Some users anecdotally report a gradually leaner look over weeks to months, but that is unverified and confounded by diet and training [13]. There is no controlled evidence that ipamorelin reduces abdominal fat in people.
Why is ipamorelin being discontinued?
Ipamorelin was never an approved drug to discontinue; its clinical development simply stopped after its only Phase 2 trial (postoperative ileus, n = 114) missed its primary endpoint [3]. Separately, access tightened in 2024 when the FDA removed ipamorelin acetate from Category 2 of the interim 503A bulk-substances list and reviewed it at the October 2024 PCAC meeting, restricting compounding-pharmacy supply.
What does CJC-1295 and ipamorelin do?
Together they push growth hormone through two complementary pathways: CJC-1295 (a GHRH analog) amplifies the GH baseline, and ipamorelin (a ghrelin-receptor agonist) adds discrete pulses without raising cortisol [1]. A 2026 review found the combination improved muscle tetanic tension in a mouse muscle-loss model, but stressed the evidence is animal-only [15]. The combination has never been tested in a human trial.
Does ipamorelin increase IGF-1?
Not always. Growth hormone normally raises liver-made IGF-1, but short rodent ipamorelin studies often show no measurable change: in the 15-day rat bone-growth study, ipamorelin increased bone growth dose-dependently with no change in total IGF-1 [4]. This suggests a partly local, GH-pulse-driven effect rather than a sustained systemic IGF-1 rise. Sustained or longer dosing could differ, but that has not been characterized in humans [1].
How does CJC-1295 ipamorelin work?
The two work through different receptors. CJC-1295 activates the GHRH receptor (a cAMP pathway), raising the underlying GH baseline. Ipamorelin activates the ghrelin receptor GHS-R1a (a calcium pathway), adding a discrete GH pulse without raising cortisol [1]. Because the pathways are separate and complementary, the combination is used to stack a sustained baseline with sharp pulses — though only the single agents, not the pair, have published pharmacology [1].
How much CJC-1295 ipamorelin should I take?
There is no evidence-based dose, because no peer-reviewed human dosing study of the combination exists. The only combination evidence is an animal muscle-tension result a 2026 review limits to mice [15]. Community subcutaneous "stack" protocols have no controlled-trial basis and are anecdotal, not recommended. This site reports the research record and does not provide a human dose.
Does CJC-1295 ipamorelin work?
For the combination, there is no human outcome trial. The strongest evidence is a mouse muscle-tension result in a glucocorticoid-induced muscle-loss model, explicitly limited to animals by the 2026 review reporting it [15]. Ipamorelin alone failed its one human efficacy trial [3] but shows real effects in animal bone and weight studies [4] [5]. So: plausible mechanism and supportive animal data, but no proof of human benefit.
How to reconstitute CJC-1295 ipamorelin 5mg?
Research-supply ipamorelin and CJC-1295 ship as a lyophilized (freeze-dried) powder and are reconstituted with bacteriostatic water for research handling, then generally kept refrigerated because peptides degrade with heat and freeze-thaw. These are general handling notes from the research-supply literature, not a clinical or dosing instruction. Because there is no approved human use, no validated "5 mg" reconstitution-to-dose procedure exists, and circulated community ratios are not study-validated [3].
How long does ipamorelin stay in your system?
The terminal half-life in humans is about two hours [2]. After roughly four to five half-lives (eight to ten hours), most of a single dose is cleared. The growth-hormone pulse it triggers peaks around 40 minutes after dosing and plays out on its own timeline [2]. For drug testing, note that detection is separate: anti-doping labs can detect GH secretagogues even after the peptide clears [7].
Does ipamorelin make you hungry?
Some users report it does. Ipamorelin acts on the ghrelin receptor — the same receptor the natural hunger hormone uses — and ghrelin-receptor agonists switch on brain appetite centers in animal studies [14]. Community reports describe an uptick in hunger after dosing, usually milder than with GHRP-6. This is a mechanism-based, class-level expectation rather than a measured human side-effect rate.
Will I gain weight on ipamorelin?
There is no human weight-change trial for ipamorelin at research-use doses. In animals it has shown both an appetite-promoting, adiposity-increasing signal (in mice, partly independent of GH) [13] and, in a different model, reduced chemotherapy-driven weight loss [5]. Anecdotally, users describe a gradually leaner look, but that is unverified and confounded [13]. The honest answer is that direction of weight change is not established in people [3].
Does ipamorelin increase appetite?
Mechanistically, yes-leaning. Ipamorelin activates the ghrelin receptor, and ghrelin-receptor agonists induce feeding by activating hypothalamic appetite centers in animal studies [14]. In mice, ipamorelin also increased adiposity and leptin partly independently of growth hormone [13]. Users commonly report increased hunger after dosing, generally milder than with GHRP-6. No controlled human appetite measurement exists at research-use doses.
What does ipamorelin peptide do?
Ipamorelin peptide releases a pulse of growth hormone by activating the ghrelin receptor GHS-R1a, and does so without raising cortisol or prolactin — its defining selectivity [1]. In animals this drove longitudinal bone growth [4] and reduced cachexia-related weight loss [5]. In its one human efficacy trial it did not speed post-surgery bowel recovery [3]. It has no approved medical use and is sold as a research chemical.
How long does it take for ipamorelin to work?
Pharmacologically, fast: after dosing, the growth-hormone pulse peaks about 40 minutes later, and the peptide's half-life is roughly two hours [2]. That is the measurable, immediate action. Any longer-term, outcome-level "working" (sleep, recovery, body composition) is anecdotal and reported by users over one to twelve weeks — not established by controlled trials, and not a clinical timeline [3].